In particular, we develop drugs and therapy for diseases that are difficult to cure or do not have available treatment. Through this, we aim to satisfy unmet medical needs and lead the world market. Drug candidates being developed at BeyondBio are innovative pipelines expected to overcome the problems of existing treatements. Product patents for these candidates have been applied for or registered not only in Korea but other major countries. We aim to become a successful model of global drug developers. We will contribute to our neighbors and society, and would like to request your big support. " CEO Changhee MIN "
| Website | http://www.beyondbio.co.kr |
| Revenue | $5.3 million |
| Employees | View employees |
| Founded | 2013 |
| Address | 1662 Yuseong-daero Yuseong-gu, Daejeon, Daejeon, KR |
| Phone | +82 42-716-0020 |
| Fax | +82 42-716-0021 |
| Industry | Manufacturing General, Drug Discovery, Manufacturing, Biotechnology |
| Competitors | Roche, Sartorius, Merck Group, Thermo Fisher Scientific, Bio-Techne, Lonza, Boehringer Ingelheim, Amgen, Receptos, a wholly-owned subsidiary of Celgene, AbbVie +53 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular BeyondBio employee's phone or email?
BeyondBio Questions
The BeyondBio annual revenue was $5.3 million in 2026.
BeyondBio is based in Daejeon, Daejeon.
The NAICS codes for BeyondBio are [32, 32541, 3254, 325].
The SIC codes for BeyondBio are [283, 28].
